Wednesday, January 24, 2018 7:34:53 AM
Agreed, this was my thinking too and thanks for providing a credible source that corroborates my thoughts and nice to see it in print. For me though this was based on the Pluristem presentation, (slide 45) "Partnerships and Collaborations", where they have clearly stated "Pluristem keeps IP and manufacturing rights in all collaborations".
Thus PSTI is only partnering for the sake of commercialisation. If they were to collaborate on any part of the IP, R&D or manufacturing of the products then it would make sense that they would then need to profit or worse knowledge share on the IP and Manufacturing too.
It will be a lot better for PSTI, provided they get any approval, that they maintain all the IP and manufacturing rights, and they use the JVs to commercialise the product as trying to commercialise it themselves in these distinct geographic and cultural areas would be an unwise and high cost undertaking when another company can just sell it for us, faster and at lower internal cost, and take a proportional % royalty of the efforts to the sale. Maintaining the IP and Manufacturing would mean that anywhere in the world if anybody wants this kinda of treatment they have to go PSTI. Very nice.
Also nice that is has been stated in this article that "Cha will perform and fund multiple clinical trials in South Korea for treating CLI and IC using PLX-PAD". This will save us/PSTI a lot of money. Then once/if the product is approved for use in Korea, PSTI and CHA can set-up the JV and begin the commercialisation.
I believe this logic as expressed in your fierce biotech article, is not only for the CHA agreement, but also the Sosei agreement as well. Again these companies will wait to see if it works, then form the JV, especially as noted for CHA that they will perform and fund multiple clinical trials. They won't want to do that until there's an approval from the FDA first. That's what I'd do if I were PSTI on the IP, or CHA on the risk/reward level.
Thanks again for sharing this Happy.
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM